L'Oréal ties part of its skincare sales momentum to the weight-loss drug boom
L'Oréal, the world's largest cosmetics company, said the boom in GLP-1 weight-loss drugs, known by brands such as Ozempic, Wegovy or Mounjaro, is boosting sales of beauty and skincare products. CEO Nicolas Hieronimus said on an investor call that the phenomenon is having an impact on consumption of these products. The company reported a 7.7% rise in third-quarter sales, above analysts' expectations.
In 30 seconds
- L'Oréal says GLP-1 use is boosting beauty and skincare consumption
- Its SkinCeuticals and Kiehl's brands have products aimed at countering skin sagging linked to rapid weight loss
- L'Oréal sales rose 7.7% in the third quarter, beating analysts' expectations
IASummary generated by artificial intelligence from a story by La Nación. It may contain errors: the original source prevails.




Comments
Be respectful. Comments reported by several people are hidden until a moderator reviews them.
You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.